The mortality rates of gastric carcinoma remain high, despite the progress in research and development in disease mechanisms and treatment. Therefore, recognition of gastric precancerous lesions and early neoplasia is crucial. Two subtypes of sporadic gastric cancer have been recognized: cardia subtype and non-cardia (distal) subtype, the latter being more frequent and largely associated with infection of Helicobacter pylori, a class I carcinogen. Helicobacter pylori initiates the widely accepted Correa cascade, describing a stepwise progression through precursor lesions from chronic inflammation to gastric atrophy, gastric intestinal metaplasia and neoplasia. Our knowledge on He-licobacter pylori is still limited, and multiple questions in the context of its contribution to the pathogenesis of gastric neoplasia are yet to be answered. Awareness and recognition of gastric atrophy and intestinal metaplasia on high-definition white-light endoscopy, image-enhanced endoscopy and magnification endoscopy, in combination with histology from the biopsies taken accurately according to the protocol, are crucial to guiding the management. Standard indications for endoscopic resections (endoscopic mucosal resection and endoscopic submucosal dissection) of gastric dysplasia and intestinal type of gastric carcinoma have been recommended by multiple societies. Endoscopic evaluation and surveillance should be offered to individuals with an inherited predisposition to gastric carcinoma.

2nd Department of Internal Medicine Gastroenterology Charles University Faculty of Medicine in Hradec Kralove and University Hospital Hradec Hralove 500 05 Hradec Kralove Czech Republic

Devision of GI Services University College London Hospital University College London Hospitals NHS Foundation Trust London NW1 2BU UK

The Royal Marsden NHS Foundation Trust London SW3 6JJ UK

Zobrazit více v PubMed

Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;144:1941–1953. doi: 10.1002/ijc.31937. PubMed DOI

Fidler M.M., Soerjomataram I., Bray F. A global view on cancer incidence and national levels of the human development index. Int. J. Cancer. 2016;139:2436–2446. doi: 10.1002/ijc.30382. PubMed DOI

Roberts S.E., Morrison-Rees S., Samuel D.G., Thorne K., Akbari A., Williams J.G. Review article: The prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment. Pharmacol. Ther. 2016;43:334–345. doi: 10.1111/apt.13474. PubMed DOI

Rawla P., Barsouk A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz. Gastroenterol. 2019;14:26–38. doi: 10.5114/pg.2018.80001. PubMed DOI PMC

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Biological agents. A review of human carcinogens. Pt BIARC Monogr. Eval. Carcinog. Risks Hum. 2012;100:1–441. PubMed PMC

Balakrishnan M., George R., Sharma A., Graham D.Y. Changing Trends in Stomach Cancer Throughout the World. Curr. Gastroenterol. Rep. 2017;19:36. doi: 10.1007/s11894-017-0575-8. PubMed DOI PMC

Abdi E., Latifi-Navid S., Zahri S., Yazdanbod A., Pourfarzi F. Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives. Cancer Med. 2019;8:6114–6126. doi: 10.1002/cam4.2497. PubMed DOI PMC

Lauren P. The Two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965;64:31–49. doi: 10.1111/apm.1965.64.1.31. PubMed DOI

Thrift A.P., Nguyen T.H. Gastric Cancer Epidemiology. Gastrointest. Endosc. Clin. N. Am. 2021;31:425–439. doi: 10.1016/j.giec.2021.03.001. PubMed DOI

Rustgi S.D., Ching C.K., Kastrinos F. Inherited Predisposition to Gastric Cancer. Gastrointest. Endosc. Clin. N. Am. 2021;31:467–487. doi: 10.1016/j.giec.2021.03.010. PubMed DOI

van der Post R.S., Oliveira C., Guilford P., Carneiro F. Hereditary gastric cancer: What’s new? Update 2013–2018. Fam. Cancer. 2019;18:363–367. doi: 10.1007/s10689-019-00127-7. PubMed DOI

Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–405. doi: 10.1038/32918. PubMed DOI

Worthley D.L., Phillips K.D., Wayte N., Schrader K.A., Healey S., Kaurah P., Shulkes A., Grimpen F., Clouston A., Moore D., et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): A new autosomal dominant syndrome. Gut. 2012;61:774–779. doi: 10.1136/gutjnl-2011-300348. PubMed DOI

Repak R., Kohoutova D., Podhola M., Rejchrt S., Minarik M., Benesova L., Lesko M., Bures J. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: Case report and review of the literature. Gastrointest. Endosc. 2016;84:718–725. doi: 10.1016/j.gie.2016.06.023. PubMed DOI

Li J., Woods S.L., Healey S., Beesley J., Chen X., Lee J.S., Sivakumaran H., Wayte N., Nones K., Waterfall J.J., et al. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am. J. Hum. Genet. 2016;98:830–842. doi: 10.1016/j.ajhg.2016.03.001. PubMed DOI PMC

Møller P., Seppälä T.T., Bernstein I., Holinski-Feder E., Sala P., Gareth Evans D., Lindblom A., Macrae F., Blanco I., Sijmons R.H., et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: A report from the Prospective Lynch Syndrome Database. Gut. 2018;67:1306–1316. doi: 10.1136/gutjnl-2017-314057. PubMed DOI PMC

Arnason T., Liang W.Y., Alfaro E., Kelly P., Chung D.C., Odze R.D., Lauwers G.Y. Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps. Histopathology. 2014;65:353–362. doi: 10.1111/his.12393. PubMed DOI

Bianchi L.K., Burke C.A., Bennett A.E., Lopez R., Hasson H., Church J.M. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin. Gastroenterol. Hepatol. 2008;6:180–185. doi: 10.1016/j.cgh.2007.11.018. PubMed DOI

Mankaney G., Leone P., Cruise M., LaGuardia L., O’Malley M., Bhatt A., Church J., Burke C.A. Gastric cancer in FAP: A concerning rise in incidence. Fam. Cancer. 2017;16:371–376. doi: 10.1007/s10689-017-9971-3. PubMed DOI

Kopacova M., Tacheci I., Rejchrt S., Bures J. Peutz-Jeghers syndrome: Diagnostic and therapeutic approach. World J. Gastroenterol. 2009;15:5397–5408. doi: 10.3748/wjg.15.5397. PubMed DOI PMC

Blatter R.H., Plasilova M., Wenzel F., Gokaslan S.T., Terracciano L., Ashfaq R., Heinimann K. Somatic alterations in juvenile polyps from BMPR1A and SMAD4 mutation carriers. Genes Chromosomes Cancer. 2015;54:575–582. doi: 10.1002/gcc.22270. PubMed DOI

Katona B.W., Powers J., McKenna D.B., Long J.M., Le A.N., Hausler R., Zelley K., Jennings S., Domchek S.M., Nathanson K.L., et al. Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. Am. J. Gastroenterol. 2020;115:2095–2097. doi: 10.14309/ajg.0000000000000935. PubMed DOI PMC

Warren J.R. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273. PubMed

Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–1275. PubMed

Goodwin C.S. Helicobacter pylori: 10th anniversary of its culture in April 1982. Gut. 1993;34:293–294. doi: 10.1136/gut.34.3.293. PubMed DOI PMC

Moran A.P., Wadström T. Pathogenesis of Helicobacter pylori. Curr. Opin. Gastroenterol. 1998;14:S9–S14.

Chmiela M., Kupcinskas J. Review: Pathogenesis of Helicobacter pylori infection. Helicobacter. 2019;24:e12638. doi: 10.1111/hel.12638. PubMed DOI PMC

Denic M., Touati E., De Reuse H. Review: Pathogenesis of Helicobacter pylori infection. Helicobacter. 2020;25:e12736. doi: 10.1111/hel.12736. PubMed DOI

Xu C., Soyfoo D.M., Wu Y., Xu S. Virulence of Helicobacter pylori outer membrane proteins: An updated review. Eur. J. Clin. Microbiol. Infect. Dis. 2020;39:1821–1830. doi: 10.1007/s10096-020-03948-y. PubMed DOI PMC

Baj J., Forma A., Sitarz M., Portincasa P., Garruti G., Krasowska D., Maciejewski R. Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment. Cells. 2020;10:27. doi: 10.3390/cells10010027. PubMed DOI PMC

Feldman M., Jensen P.J., Howden C.W. Gastritis and gastropathy. In: Feldman M., Friedman L.S., Chung T., Rubin D.T., Wilcox C.M., editors. Sleisenger and Fordtrans Gastrointestinal and Liver Disease. 11th ed. Elsevier; Amsterdam, The Netherlands: 2021. pp. 781–805.

Ansari S., Yamaoka Y. Helicobacter pylori Virulence Factor Cytotoxin-Associated Gene A (CagA)-Mediated Gastric Pathogenicity. Int. J. Mol. Sci. 2020;21:7430. doi: 10.3390/ijms21197430. PubMed DOI PMC

Chiba N. Ulcer disease and Helicobacter pylori infection: Current treatment. In: McDonald J.W.D., Feagan B.G., Jalan R., Kahrilas P.J., editors. Evidece-Based Gastroenterology and Hepatology. 4th ed. Wiley Blackwell; Oxford, UK: 2019. pp. 68–85.

Kontizas E., Tastsoglou S., Karamitros T., Karayiannis Y., Kollia P., Hatzigeorgiou A.G., Sgouras D.N. Impact of Helicobacter pylori Infection and Its Major Virulence Factor CagA on DNA Damage Repair. Microorganisms. 2020;8:2007. doi: 10.3390/microorganisms8122007. PubMed DOI PMC

Alipour M. Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer. J. Gastrointest. Cancer. 2021;52:23–30. doi: 10.1007/s12029-020-00518-5. PubMed DOI PMC

Quante M., Bornschein J. Adenocarcinoma of the stomach and other gastric tumors. Gastritis and gastropathy. In: Feldman M., Friedman L.S., Chung T., Rubin D.T., Wilcox C.M., editors. Sleisenger and Fordtrans Gastrointestinal and Liver Disease. 11th ed. Elsevier; Amsterdam, The Netherlands: 2021. pp. 820–841.

Forman D., Newell D.G., Fullerton F., Yarnell J.W., Stacey A.R., Wald N., Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. Br. Med. J. 1991;302:1302–1305. doi: 10.1136/bmj.302.6788.1302. PubMed DOI PMC

Sierra R., Muñoz N., Peña A.S., Biemond I., van Duijn W., Lamers C.B., Teuchmann S., Hernandez S., Correa P. Antibodies to Helicobacter pylori and pepsinogen levels in children from Costa Rica: Comparison of two areas with different risks for stomach cancer. Cancer Epidemiol. Biomarkers Prev. 1992;1:449–454. PubMed

Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman J.H., Orentreich N., Sibley R.K. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 1991;325:1127–1131. doi: 10.1056/NEJM199110173251603. PubMed DOI

Nomura A., Stemmermann G.N., Chyou P.H., Kato I., Perez-Perez G.I., Blaser M.J. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med. 1991;325:1132–1136. doi: 10.1056/NEJM199110173251604. PubMed DOI

Talley N.J., Zinsmeister A.R., Weaver A., DiMagno E.P., Carpenter H.A., Perez-Perez G.I., Blaser M.J. Gastric adenocarcinoma and Helicobacter pylori infection. J. Natl. Cancer Inst. 1991;83:1734–1739. doi: 10.1093/jnci/83.23.1734. PubMed DOI

Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 1994;61:1–241. PubMed PMC

Watanabe T., Tada M., Nagai H., Sasaki S., Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology. 1998;115:642–648. doi: 10.1016/S0016-5085(98)70143-X. PubMed DOI

Petersen C.P., Mills J.C., Goldenring J.R. Murine Models of Gastric Corpus Preneoplasia. Cell. Mol. Gastroenterol. Hepatol. 2016;3:11–26. doi: 10.1016/j.jcmgh.2016.11.001. PubMed DOI PMC

Hayakawa Y., Fox J.G., Wang T.C. The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models. Cell. Mol. Gastroenterol. Hepatol. 2017;3:331–338. doi: 10.1016/j.jcmgh.2017.01.013. PubMed DOI PMC

Correa P. Human gastric carcinogenesis: A multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–6740. PubMed

Fox J.G., Wang T.C. Inflammation, atrophy, and gastric cancer. J. Clin. Investig. 2007;117:60–69. doi: 10.1172/JCI30111. PubMed DOI PMC

Guo Y., Zhang Y., Gerhard M., Gao J.J., Mejias-Luque R., Zhang L., Vieth M., Ma J.L., Bajbouj M., Suchanek S., et al. Effect of Helicobacter pylori on gastrointestinal microbiota: A population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69:1598–1607. doi: 10.1136/gutjnl-2019-319696. PubMed DOI PMC

Kadeerhan G., Gerhard M., Gao J.J., Mejías-Luque R., Zhang L., Vieth M., Ma J.L., Bajbouj M., Suchanek S., Liu W.D., et al. Microbiota alteration at different stages in gastric lesion progression: A population-based study in Linqu, China. Am. J. Cancer Res. 2021;11:561–575. PubMed PMC

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., Plummer M. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 2012;13:607–615. doi: 10.1016/S1470-2045(12)70137-7. PubMed DOI

GBD 2017 Stomach Cancer Collaborators The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol. Hepatol. 2020;5:42–54. doi: 10.1016/S2468-1253(19)30328-0. PubMed DOI PMC

Thrift A.P., El-Serag H.B. Burden of gastric cancer. Clin. Gastroenterol. Hepatol. 2020;18:534–542. doi: 10.1016/j.cgh.2019.07.045. PubMed DOI PMC

Lee Y.C., Chiang T.H., Chou C.K., Tu Y.K., Liao W.C., Wu M.S., Graham D.Y. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150:1113–1124.e5. doi: 10.1053/j.gastro.2016.01.028. PubMed DOI

Seta T., Takahashi Y., Noguchi Y., Shikata S., Sakai T., Sakai K., Yamashita Y., Nakayama T. Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference. PLoS ONE. 2017;12:e0183321. doi: 10.1371/journal.pone.0183321. PubMed DOI PMC

Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., et al. Management of Helicobacter pylori infection: The Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30. doi: 10.1136/gutjnl-2016-312288. PubMed DOI

Pimentel-Nunes P., Libânio D., Marcos-Pinto R., Areia M., Leja M., Esposito G., Garrido M., Kikuste I., Megraud F., Matysiak-Budnik T., et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365–388. PubMed

Ford A.C., Yuan Y., Forman D., Hunt R., Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst. Rev. 2020;7:CD005583. PubMed PMC

Ford A.C., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: Systematic review and meta-analysis. Gut. 2020;69:2113–2121. doi: 10.1136/gutjnl-2020-320839. PubMed DOI

Liou J.M., Malfertheiner P., Lee Y.C., Sheu B.S., Sugano K., Cheng H.C., Yeoh K.G., Hsu P.I., Goh K.L., Mahachai V., et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: The Taipei global consensus. Gut. 2020;69:2093–2112. doi: 10.1136/gutjnl-2020-322368. PubMed DOI

Katelaris P., Hunt R., Bazzoli F., Cohen H., Fock K.M., Gemilyan M., Malfertheiner P., Mégraud F., Piscoya A., Quach D., et al. Helicobacter pylori. World Gastroenterology Organisation Global Guidelines. World Gastroenterology Organisation. Apr, 2021. [(accessed on 27 August 2021)]. Available online: https://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2021.pdf.

Inoue M. Public Health Interventions for Gastric Cancer Control. Gastrointest. Endosc. Clin. N. Am. 2021;31:441–449. doi: 10.1016/j.giec.2021.03.002. PubMed DOI

Kim J., Wang T.C. Helicobacter pylori and Gastric Cancer. Gastrointest. Endosc. Clin. N. Am. 2021;31:451–465. doi: 10.1016/j.giec.2021.03.003. PubMed DOI

Huang R.J., Hwang J.H. Improving the Early Diagnosis of Gastric Cancer. Gastrointest. Endosc. Clin. N. Am. 2021;31:503–517. doi: 10.1016/j.giec.2021.03.005. PubMed DOI PMC

Fuccio L., Zagari R.M., Eusebi L.H., Laterza L., Cennamo V., Ceroni L., Grilli D., Bazzoli F. Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 2009;151:121–128. doi: 10.7326/0003-4819-151-2-200907210-00009. PubMed DOI

Ford A.C., Forman D., Hunt R.H., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials. Br. Med. J. 2014;348:g3174. doi: 10.1136/bmj.g3174. PubMed DOI PMC

Uemura N., Mukai T., Okamoto S., Yamaguchi S., Mashiba H., Taniyama K., Sasaki N., Haruma K., Sumii K., Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1997;6:639–642. doi: 10.1016/S0889-8553(05)70149-7. PubMed DOI

Forbes G.M., Threlfall T.J. Treatment of Helicobacter pylori infection to reduce gastric cancer incidence: Uncertain benefits of a community based programme in Australia. J. Gastroenterol. Hepatol. 1998;13:1091–1095. doi: 10.1111/j.1440-1746.1998.tb00581.x. PubMed DOI

Wong B.C., Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., Lai K.C., Hu W.H., Yuen S.T., Leung S.Y., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. J. Am. Med. Assoc. 2004;291:187–194. doi: 10.1001/jama.291.2.187. PubMed DOI

Pisegna J.R., Surti B., Scott D.R. Clinical trial report: Eradication of Helicobacter pylori reduces the risk for subsequent gastric cancer. Curr. Gastroenterol. Rep. 2010;12:427–430. doi: 10.1007/s11894-010-0138-8. PubMed DOI PMC

Kosunen T.U., Pukkala E., Sarna S., Seppälä K., Aromaa A., Knekt P., Rautelin H. Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study. Int. J. Cancer. 2011;128:433–439. doi: 10.1002/ijc.25337. PubMed DOI

Kwon Y.H., Heo J., Lee H.S., Cho C.M., Jeon S.W. Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. Aliment. Pharmacol. Ther. 2014;39:609–618. doi: 10.1111/apt.12633. PubMed DOI

Shiotani A., Haruma K., Graham D.Y. Metachronous gastric cancer after successful Helicobacter pylori eradication. World J. Gastroenterol. 2014;20:11552–11559. doi: 10.3748/wjg.v20.i33.11552. PubMed DOI PMC

Uno K., Iijima K., Shimosegawa T. Gastric cancer development after the successful eradication of Helicobacter pylori. World J. Gastrointest. Oncol. 2016;8:271–281. doi: 10.4251/wjgo.v8.i3.271. PubMed DOI PMC

Choi I.J., Kook M.C., Kim Y.I., Cho S.J., Lee J.Y., Kim C.G., Park B., Nam B.H. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N. Engl. J. Med. 2018;378:1085–1095. doi: 10.1056/NEJMoa1708423. PubMed DOI

Zhao B., Zhang J., Mei D., Luo R., Lu H., Xu H., Huang B. Does Helicobacter pylori Eradication Reduce the Incidence of Metachronous Gastric Cancer After Curative Endoscopic Resection of Early Gastric Cancer: A Systematic Review and Meta-Analysis. J. Clin. Gastroenterol. 2020;54:235–241. doi: 10.1097/MCG.0000000000001195. PubMed DOI

den Hoed C.M., Holster I.L., Capelle L.G., de Vries A.C., den Hartog B., Ter Borg F., Biermann K., Kuipers E.J. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy. 2013;45:249–256. doi: 10.1055/s-0032-1326379. PubMed DOI

Pan K.F., Zhang L., Gerhard M., Ma J.L., Liu W.D., Ulm K., Wang J.X., Zhang L., Zhang Y., Bajbouj M., et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: Baseline results and factors affecting the eradication. Gut. 2016;65:9–18. doi: 10.1136/gutjnl-2015-309197. PubMed DOI

Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., Terao S., Amagai K., Hayashi S., Asaka M., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 2008;372:392–397. doi: 10.1016/S0140-6736(08)61159-9. PubMed DOI

Graham D.Y., Zou W.Y. Guilt by association: Intestinal metaplasia does not progress to gastric cancer. Curr. Opin. Gastroenterol. 2018;34:458–464. doi: 10.1097/MOG.0000000000000472. PubMed DOI PMC

Bures J., Kopacova M., Koupil I., Vorisek V., Rejchrt S., Beranek M., Seifert B., Pozler O., Zivny P., Douda T., et al. Epidemiology of Helicobacter pylori infection in the Czech Republic. Helicobacter. 2006;11:56–65. doi: 10.1111/j.0083-8703.2006.00369.x. PubMed DOI

Bures J., Kopacova M., Koupil I., Seifert B., Skodova Fendrichova M., Spirkova J., Vorisek V., Rejchrt S., Douda T., Kral N., et al. Significant decrease in prevalence of Helicobacter pylori in the Czech Republic. World J. Gastroenterol. 2012;18:4412–4418. doi: 10.3748/wjg.v18.i32.4412. PubMed DOI PMC

Institute of Health Information and Statistics of the Czech Republic. [(accessed on 27 August 2021)]. Available online: www.uzis.cz.

den Hoed C.M., Vila A.J., Holster I.L., Perez-Perez G.I., Blaser M.J., de Jongste J.C., Kuipers E.J. Helicobacter pylori and the birth cohort effect: Evidence for stabilized colonization rates in childhood. Helicobacter. 2011;16:405–409. doi: 10.1111/j.1523-5378.2011.00854.x. PubMed DOI PMC

Blaser M.J. Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease. J. Infect. Dis. 1999;179:1523–1530. doi: 10.1086/314785. PubMed DOI

Blaser M.J. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep. 2006;7:956–960. doi: 10.1038/sj.embor.7400812. PubMed DOI PMC

Blaser M.J. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev. Res. 2008;1:308–311. doi: 10.1158/1940-6207.CAPR-08-0170. PubMed DOI

Blaser M.J., Chyou P.H., Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res. 1995;55:562–565. PubMed

Hansson L.E., Nyrén O., Hsing A.W., Bergström R., Josefsson S., Chow W.H., Fraumeni J.F., Jr., Adami H.O. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N. Engl. J. Med. 1996;335:242–249. doi: 10.1056/NEJM199607253350404. PubMed DOI

Graham D.Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: A model. Gastroenterology. 1997;113:1983–1991. doi: 10.1016/S0016-5085(97)70019-2. PubMed DOI

Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001;345:784–789. doi: 10.1056/NEJMoa001999. PubMed DOI

Hsu P.I., Li C.N., Tseng H.H., Lai K.H., Hsu P.N., Lo G.H., Lo C.C., Yeh J.J., Ger L.P., Hsiao M., et al. The interleukin-1 RN polymorphism and Helicobacter pylori infection in the development of duodenal ulcer. Helicobacter. 2004;9:605–613. doi: 10.1111/j.1083-4389.2004.00277.x. PubMed DOI

Tahara T., Arisawa T., Wang F., Shibata T., Nakamura M., Sakata M., Hirata I., Nakano H. Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. Dig. Dis. Sci. 2008;53:919–924. doi: 10.1007/s10620-007-9950-x. PubMed DOI

Ubukata H., Nagata H., Tabuchi T., Konishi S., Kasuga T., Tabuchi T. Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer. Gastric Cancer. 2011;14:4–12. doi: 10.1007/s10120-011-0005-9. PubMed DOI

Datta De D., Roychoudhury S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J. Gastroenterol. 2015;21:2883–2895. doi: 10.3748/wjg.v21.i10.2883. PubMed DOI PMC

Henrik Simán J., Forsgren A., Berglund G., Florén C.H. Helicobacter pylori infection is associated with a decreased risk of developing oesophageal neoplasms. Helicobacter. 2001;6:310–316. doi: 10.1046/j.1523-5378.2001.00041.x. PubMed DOI

Tacheci I., Repak R., Podhola M., Benesova L., Cyrany J., Bures J., Kohoutova D. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)—A Helicobacter-opposite point. Best Pract. Res. Clin. Gastroenterol. 2021;50–51:101728. doi: 10.1016/j.bpg.2021.101728. PubMed DOI

Waldum H., Fossmark R. Gastritis, Gastric Polyps and Gastric Cancer. Int. J. Mol. Sci. 2021;22:6548. doi: 10.3390/ijms22126548. PubMed DOI PMC

Lundell L., Vieth M., Gibson F., Nagy P., Kahrilas P.J. Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment. Pharmacol. Ther. 2015;42:649–663. doi: 10.1111/apt.13324. PubMed DOI

Cheung K.S., Leung W.K. Long-term use of proton-pump inhibitors and risk of gastric cancer: A review of the current evidence. Ther. Adv. Gastroenterol. 2019;12:1756284819834511. doi: 10.1177/1756284819834511. PubMed DOI PMC

Brusselaers N., Wahlin K., Engstrand L., Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739. doi: 10.1136/bmjopen-2017-017739. PubMed DOI PMC

Helgadottir H., Bjornsson E.S. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int. J. Mol. Sci. 2019;20:5469. doi: 10.3390/ijms20215469. PubMed DOI PMC

Holcombe C. Helicobacter pylori: The African enigma. Gut. 1992;33:429–431. doi: 10.1136/gut.33.4.429. PubMed DOI PMC

Ghoshal U.C., Chaturvedi R., Correa P. The enigma of Helicobacter pylori infection and gastric cancer. Indian J. Gastroenterol. 2010;29:95–100. doi: 10.1007/s12664-010-0024-1. PubMed DOI PMC

Zaidi S.F. Helicobacter pylori associated Asian enigma: Does diet deserve distinction? World J. Gastrointest. Oncol. 2016;8:341–350. doi: 10.4251/wjgo.v8.i4.341. PubMed DOI PMC

Miller A.K., Williams S.M. Helicobacter pylori infection causes both protective and deleterious effects in human health and disease. Genes Immun. 2021;22:218–226. doi: 10.1038/s41435-021-00146-4. PubMed DOI PMC

Fox J.G., Wang T.C., Nagler-Anderson C. The African enigma: The parasite’s perspective. Gut. 2001;49:156–157. doi: 10.1136/gut.49.1.156a. PubMed DOI PMC

Whary M.T., Sundina N., Bravo L.E., Correa P., Quinones F., Caro F., Fox J.G. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: Possible implications for gastric carcinogenesis. Cancer Epidemiol. Biomarkers Prev. 2005;14:1464–1469. doi: 10.1158/1055-9965.EPI-05-0095. PubMed DOI

Hussain Z., El-Omar E., Lee Y.Y. Dual infective burden of Helicobacter pylori and intestinal parasites: Good or bad news for the host? Indian J. Gastroenterol. 2020;39:111–116. doi: 10.1007/s12664-020-01045-8. PubMed DOI

Agha A., Graham D.Y. Evidence-based examination of the African enigma in relation to Helicobacter pylori infection. Scand. J. Gastroenterol. 2005;40:523–529. doi: 10.1080/00365520510012280. PubMed DOI

Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554–3560. PubMed

Correa P., Piazuelo M.B., Wilson K.T. Pathology of gastric intestinal metaplasia: Clinical implications. Am. J. Gastroenterol. 2010;105:493–498. doi: 10.1038/ajg.2009.728. PubMed DOI PMC

Banks M., Graham D., Jansen M., Gotoda T., Coda S., di Pietro M., Uedo N., Bhandari P., Pritchard D.M., Kuipers E.J., et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68:1545–1575. doi: 10.1136/gutjnl-2018-318126. PubMed DOI PMC

Park Y.H., Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J. Cancer Prev. 2015;20:25–40. doi: 10.15430/JCP.2015.20.1.25. PubMed DOI PMC

Zullo A., Hassan C., Romiti A., Giusto M., Guerriero C., Lorenzetti R., Campo S.M., Tomao S. Follow-up of intestinal metaplasia in the stomach: When, how and why. World J. Gastrointest. Oncol. 2012;4:30–36. doi: 10.4251/wjgo.v4.i3.30. PubMed DOI PMC

You W.C., Li J.Y., Blot W.J., Chang Y.S., Jin M.L., Gail M.H., Zhang L., Liu W.D., Ma J.L., Hu Y.R., et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int. J. Cancer. 1999;83:615–619. doi: 10.1002/(SICI)1097-0215(19991126)83:5<615::AID-IJC8>3.0.CO;2-L. PubMed DOI

de Vries A.C., van Grieken N.C., Looman C.W., Casparie M.K., de Vries E., Meijer G.A., Kuipers E.J. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–952. doi: 10.1053/j.gastro.2008.01.071. PubMed DOI

Leung W.K., Lin S.R., Ching J.Y., To K.F., Ng E.K., Chan F.K., Lau J.Y., Sung J.J. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on Helicobacter pylori eradication. Gut. 2004;53:1244–1249. doi: 10.1136/gut.2003.034629. PubMed DOI PMC

Pérez-Rodríguez M., Partida-Rodríguez O., Camorlinga-Ponce M., Flores-Luna L., Lazcano E., Gómez A., Herrera-Goepfert R., Medrano-Guzmán R., Torres J. Polymorphisms in HLA-DQ genes, together with age, sex, and Helicobacter pylori infection, as potential biomarkers for the early diagnosis of gastric cancer. Helicobacter. 2017;22:e12326. doi: 10.1111/hel.12326. PubMed DOI

Engel L.S., Chow W.H., Vaughan T.L., Gammon M.D., Risch H.A., Stanford J.L., Schoenberg J.B., Mayne S.T., Dubrow R., Rotterdam H., et al. Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst. 2003;95:1404–1413. doi: 10.1093/jnci/djg047. PubMed DOI

Sjödahl K., Lu Y., Nilsen T.I., Ye W., Hveem K., Vatten L., Lagergren J. Smoking and alcohol drinking in relation to risk of gastric cancer: A population-based, prospective cohort study. Int. J. Cancer. 2007;120:128–132. doi: 10.1002/ijc.22157. PubMed DOI

Song J.H., Kim Y.S., Heo N.J., Lim J.H., Yang S.Y., Chung G.E., Kim J.S. High Salt Intake Is Associated with Atrophic Gastritis with Intestinal Metaplasia. Cancer Epidemiol. Biomarkers Prev. 2017;26:1133–1138. doi: 10.1158/1055-9965.EPI-16-1024. PubMed DOI

Vannella L., Lahner E., Osborn J., Annibale B. Systematic review: Gastric cancer incidence in pernicious anaemia. Aliment. Pharmacol. Ther. 2013;37:375–382. doi: 10.1111/apt.12177. PubMed DOI

Spence A.D., Cardwell C.R., McMenamin Ú.C., Hicks B.M., Johnston B.T., Murray L.J., Coleman H.G. Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: A systematic review. BMC Gastroenterol. 2017;17:157. doi: 10.1186/s12876-017-0708-4. PubMed DOI PMC

Vannella L., Lahner E., Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World J. Gastroenterol. 2012;18:1279–1285. doi: 10.3748/wjg.v18.i12.1279. PubMed DOI PMC

Choi A.Y., Strate L.L., Fix M.C., Schmidt R.A., Ende A.R., Yeh M.M., Inadomi J.M., Hwang J.H. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. Gastrointest. Endosc. 2018;87:1023–1028. doi: 10.1016/j.gie.2017.11.010. PubMed DOI

González C.A., Sanz-Anquela J.M., Companioni O., Bonet C., Berdasco M., López C., Mendoza J., Martín-Arranz M.D., Rey E., Poves E., et al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: Results of the Spanish follow-up multicenter study. J. Gastroenterol. Hepatol. 2016;31:953–958. doi: 10.1111/jgh.13249. PubMed DOI

Dinis-Ribeiro M., Lopes C., da Costa-Pereira A., Guilherme M., Barbosa J., Lomba-Viana H., Silva R., Moreira-Dias L. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J. Clin. Pathol. 2004;57:177–182. doi: 10.1136/jcp.2003.11270. PubMed DOI PMC

Shichijo S., Hirata Y., Niikura R., Hayakawa Y., Yamada A., Ushiku T., Fukayama M., Koike K. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest. Endosc. 2016;84:618–624. doi: 10.1016/j.gie.2016.03.791. PubMed DOI

den Hollander W.J., Holster I.L., den Hoed C.M., Capelle L.G., Tang T.J., Anten M.P., Prytz-Berset I., Witteman E.M., Ter Borg F., Hartog G.D., et al. Surveillance of premalignant gastric lesions: A multicentre prospective cohort study from low incidence regions. Gut. 2019;68:585–593. doi: 10.1136/gutjnl-2017-314498. PubMed DOI

Matsuoka T., Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J. Gastroenterol. 2018;24:2818–2832. doi: 10.3748/wjg.v24.i26.2818. PubMed DOI PMC

Leja M., Linē A. Early detection of gastric cancer beyond endoscopy—New methods. Best Pract. Res. Clin. Gastroenterol. 2021;50–51:101731. doi: 10.1016/j.bpg.2021.101731. PubMed DOI

Wu D., Zhang P., Ma J., Xu J., Yang L., Xu W., Que H., Chen M., Xu H. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019;8:1576–1583. doi: 10.1002/cam4.2055. PubMed DOI PMC

Shi Y., Wang Z., Zhu X., Chen L., Ma Y., Wang J., Yang X., Liu Z. Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer. Int. J. Clin. Oncol. 2020;25:89–99. doi: 10.1007/s10147-019-01532-9. PubMed DOI

Yuan L., Xu Z.Y., Ruan S.M., Mo S., Qin J.J., Cheng X.D. Long non-coding RNAs towards precision medicine in gastric cancer: Early diagnosis, treatment, and drug resistance. Mol. Cancer. 2020;19:96. doi: 10.1186/s12943-020-01219-0. PubMed DOI PMC

Huang Z.B., Zhang H.T., Yu B., Yu D.H. Cell-free DNA as a liquid biopsy for early detection of gastric cancer. Oncol. Lett. 2021;21:3. doi: 10.3892/ol.2020.12264. PubMed DOI PMC

Herrera-Pariente C., Montori S., Llach J., Bofill A., Albeniz E., Moreira L. Biomarkers for Gastric Cancer Screening and Early Diagnosis. Biomedicines. 2021;9:1448. doi: 10.3390/biomedicines9101448. PubMed DOI PMC

Calanzani N., Druce P.E., Snudden C., Milley K.M., Boscott R., Behiyat D., Saji S., Martinez-Gutierrez J., Oberoi J., Funston G., et al. Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review. Adv. Ther. 2021;38:793–834. doi: 10.1007/s12325-020-01571-z. PubMed DOI PMC

Nozaki K., Ogawa M., Williams J.A., Lafleur B.J., Ng V., Drapkin R.I., Mills J.C., Konieczny S.F., Nomura S., Goldenring J.R. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology. 2008;134:511–522. doi: 10.1053/j.gastro.2007.11.058. PubMed DOI PMC

Weis V.G., Goldenring J.R. Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer. 2009;12:189–197. doi: 10.1007/s10120-009-0527-6. PubMed DOI PMC

Goldenring J.R., Nam K.T., Wang T.C., Mills J.C., Wright N.A. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: Time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology. 2010;138:2207–2210. doi: 10.1053/j.gastro.2010.04.023. PubMed DOI PMC

Leja M., Funka K., Janciauskas D., Putnins V., Ruskule A., Kikuste I., Kojalo U., Tolmanis I., Misins J., Purmalis K., et al. Interobserver variation in assessment of gastric premalignant lesions: Higher agreement for intestinal metaplasia than for atrophy. Eur. J. Gastroenterol. Hepatol. 2013;25:694–699. doi: 10.1097/MEG.0b013e32835e3397. PubMed DOI

Rugge M., Fassan M., Pizzi M., Farinati F., Sturniolo G.C., Plebani M., Graham D.Y. Operative link for gastritis assessment vs. operative link on intestinal metaplasia assessment. World J. Gastroenterol. 2011;17:4596–4601. doi: 10.3748/wjg.v17.i41.4596. PubMed DOI PMC

Capelle L.G., de Vries A.C., Haringsma J., Ter Borg F., de Vries R.A., Bruno M.J., van Dekken H., Meijer J., van Grieken N.C., Kuipers E.J. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest. Endosc. 2010;71:1150–1158. doi: 10.1016/j.gie.2009.12.029. PubMed DOI

Kono S., Gotoda T., Yoshida S., Oda I., Kondo H., Gatta L., Naylor G., Dixon M., Moriyasu F., Axon A. Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. World J. Gastroenterol. 2015;21:13113–13123. doi: 10.3748/wjg.v21.i46.13113. PubMed DOI PMC

Esposito G., Pimentel-Nunes P., Angeletti S., Castro R., Libânio D., Galli G., Lahner E., Di Giulio E., Annibale B., Dinis-Ribeiro M. Endoscopic grading of gastric intestinal metaplasia (EGGIM): A multicenter validation study. Endoscopy. 2019;51:515–521. doi: 10.1055/a-0808-3186. PubMed DOI

Dai Y.C., Tang Z.P., Zhang Y.L. How to assess the severity of atrophic gastritis. World J. Gastroenterol. 2011;17:1690–1693. doi: 10.3748/wjg.v17.i13.1690. PubMed DOI PMC

An J.K., Song G.A., Kim G.H., Park D.Y., Shin N.R., Lee B.E., Woo H.Y., Ryu D.Y., Kim D.U., Heo J. Marginal turbid band and light blue crest, signs observed in magnifying narrow-band imaging endoscopy, are indicative of gastric intestinal metaplasia. BMC Gastroenterol. 2012;12:169. doi: 10.1186/1471-230X-12-169. PubMed DOI PMC

ASGE Standards of Practice Committee. Evans J.A., Chandrasekhara V., Chathadi K.V., Decker G.A., Early D.S., Fisher D.A., Foley K., Hwang J.H., Jue T.L., et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest. Endosc. 2015;82:1–8. PubMed

Zhu L., Qin J., Wang J., Guo T., Wang Z., Yang J. Early Gastric Cancer: Current Advances of Endoscopic Diagnosis and Treatment. Gastroenterol. Res. Pract. 2016;2016:9638041. doi: 10.1155/2016/9638041. PubMed DOI PMC

Bisschops R., Areia M., Coron E., Dobru D., Kaskas B., Kuvaev R., Pech O., Ragunath K., Weusten B., Familiari P., et al. Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative. United Eur. Gastroenterol. J. 2016;4:629–656. doi: 10.1177/2050640616664843. PubMed DOI PMC

Beg S., Ragunath K., Wyman A., Banks M., Trudgill N., Pritchard D.M., Riley S., Anderson J., Griffiths H., Bhandari P., et al. Quality standards in upper gastrointestinal endoscopy: A position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS) Gut. 2017;66:1886–1899. doi: 10.1136/gutjnl-2017-314109. PubMed DOI PMC

Park C.H., Yang D.H., Kim J.W., Kim J.H., Kim J.H., Min Y.W., Lee S.H., Bae J.H., Chung H., Choi K.D., et al. Clinical practice guideline for endoscopic resection of early gastrointestinal cancer. Intest. Res. 2021;19:127–157. doi: 10.5217/ir.2020.00020. PubMed DOI PMC

Teh J.L., Tan J.R., Lau L.J., Saxena N., Salim A., Tay A., Shabbir A., Chung S., Hartman M., So J.B. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. Clin. Gastroenterol. Hepatol. 2015;13:480–487.e2. doi: 10.1016/j.cgh.2014.07.059. PubMed DOI

Kawamura T., Wada H., Sakiyama N., Ueda Y., Shirakawa A., Okada Y., Sanada K., Nakase K., Mandai K., Suzuki A., et al. Examination time as a quality indicator of screening upper gastrointestinal endoscopy for asymptomatic examinees. Dig. Endosc. 2017;29:569–575. doi: 10.1111/den.12804. PubMed DOI

Park J.M., Huo S.M., Lee H.H., Lee B.I., Song H.J., Choi M.G. Longer Observation Time Increases Proportion of Neoplasms Detected by Esophagogastroduodenoscopy. Gastroenterology. 2017;153:460–469.e1. doi: 10.1053/j.gastro.2017.05.009. PubMed DOI

Yoshimizu S., Hirasawa T., Horiuchi Y., Omae M., Ishiyama A., Yoshio T., Tsuchida T., Fujisaki J. Differences in upper gastrointestinal neoplasm detection rates based on inspection time and esophagogastroduodenoscopy training. Endosc. Int. Open. 2018;6:E1190–E1197. doi: 10.1055/a-0655-7382. PubMed DOI PMC

Waddingham W., Nieuwenburg S.A.V., Carlson S., Rodriguez-Justo M., Spaander M., Kuipers E.J., Jansen M., Graham D.G., Banks M. Recent advances in the detection and management of early gastric cancer and its precursors. Frontline Gastroenterol. 2020;12:322–331. doi: 10.1136/flgastro-2018-101089. PubMed DOI PMC

Asge Technology Committee. Song L.M., Adler D.G., Conway J.D., Diehl D.L., Farraye F.A., Kantsevoy S.V., Kwon R., Mamula P., Rodriguez B., et al. Narrow band imaging and multiband imaging. Gastrointest. Endosc. 2008;67:581–589. PubMed

Matsumoto K., Ueyama H., Yao T., Abe D., Oki S., Suzuki N., Ikeda A., Yatagai N., Akazawa Y., Komori H., et al. Diagnostic limitations of magnifying endoscopy with narrow-band imaging in early gastric cancer. Endosc. Int. Open. 2020;8:E1233–E1242. doi: 10.1055/a-1220-6389. PubMed DOI PMC

Osawa H., Yamamoto H., Miura Y., Yoshizawa M., Sunada K., Satoh K., Sugano K. Diagnosis of extent of early gastric cancer using flexible spectral imaging color enhancement. World J. Gastrointest. Endosc. 2012;4:356–361. doi: 10.4253/wjge.v4.i8.356. PubMed DOI PMC

Nishimura J., Nishikawa J., Nakamura M., Goto A., Hamabe K., Hashimoto S., Okamoto T., Suenaga M., Fujita Y., Hamamoto Y., et al. Efficacy of i-Scan Imaging for the Detection and Diagnosis of Early Gastric Carcinomas. Gastroenterol. Res. Pract. 2014;2014:819395. doi: 10.1155/2014/819395. PubMed DOI PMC

Kaneko K., Oono Y., Yano T., Ikematsu H., Odagaki T., Yoda Y., Yagishita A., Sato A., Nomura S. Effect of novel bright image enhanced endoscopy using blue laser imaging (BLI) Endosc. Int. Open. 2014;2:E212–E219. doi: 10.1055/s-0034-1390707. PubMed DOI PMC

Wang L., Huang W., Du J., Chen Y., Yang J. Diagnostic yield of the light blue crest sign in gastric intestinal metaplasia: A meta-analysis. PLoS ONE. 2014;9:e92874. doi: 10.1371/journal.pone.0092874. PubMed DOI PMC

Dinis-Ribeiro M. Chromoendoscopy for early diagnosis of gastric cancer. Eur. J. Gastroenterol. Hepatol. 2006;18:831–838. doi: 10.1097/00042737-200608000-00005. PubMed DOI

Singh R., Chiam K.H., Leiria F., Pu L.Z.C.T., Choi K.C., Militz M. Chromoendoscopy: Role in modern endoscopic imaging. Transl. Gastroenterol. Hepatol. 2020;5:39. doi: 10.21037/tgh.2019.12.06. PubMed DOI PMC

Ojetti V., Persiani R., Nista E.C., Rausei S., Lecca G., Migneco A., Cananzi F.C., Cammarota G., D’Ugo D., Gasbarrini G., et al. A case-control study comparing methylene blue directed biopsies and random biopsies for detecting pre-cancerous lesions in the follow-up of gastric cancer patients. Eur. Rev. Med. Pharmacol. Sci. 2007;11:291–296. doi: 10.1016/S1590-8658(06)80402-0. PubMed DOI

Dinis-Ribeiro M., da Costa-Pereira A., Lopes C., Moreira-Dias L. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J. Gastroenterol. Hepatol. 2007;22:1594–1604. doi: 10.1111/j.1440-1746.2007.04863.x. PubMed DOI

Taghavi S.A., Membari M.E., Eshraghian A., Dehghani S.M., Hamidpour L., Khademalhoseini F. Comparison of chromoendoscopy and conventional endoscopy in the detection of premalignant gastric lesions. Can. J. Gastroenterol. 2009;23:105–108. doi: 10.1155/2009/594983. PubMed DOI PMC

Eleftheriadis N., Inoue H., Ikeda H., Onimaru M., Yoshida A., Maselli R., Santi G., Kudo S.E. Acetic acid spray enhances accuracy of narrow-band imaging magnifying endoscopy for endoscopic tissue characterization of early gastric cancer. Gastrointest. Endosc. 2014;79:712. doi: 10.1016/j.gie.2013.11.033. PubMed DOI

Yao K. The endoscopic diagnosis of early gastric cancer. Ann. Gastroenterol. 2013;26:11–22. PubMed PMC

An P., Yang D., Wang J., Wu L., Zhou J., Zeng Z., Huang X., Xiao Y., Hu S., Chen Y., et al. A deep learning method for delineating early gastric cancer resection margin under chromoendoscopy and white light endoscopy. Gastric Cancer. 2020;23:884–892. doi: 10.1007/s10120-020-01071-7. PubMed DOI

Ohnita K., Isomoto H., Shikuwa S., Yamaguchi N., Nakayama T., Nishiyama H., Okamoto K., Fukuda E., Takeshima F., Hayashi T., et al. Magnifying chromoendoscopic findings of early gastric cancer and gastric adenoma. Dig. Dis. Sci. 2011;56:2715–2722. doi: 10.1007/s10620-011-1638-6. PubMed DOI

Zheng X., Mao X., Xu K., Lü L., Peng X., Wang M., Xu G., Hua Z., Wang J., Xue H., et al. Massive Endoscopic Screening for Esophageal and Gastric Cancers in a High-Risk Area of China. PLoS ONE. 2015;10:e0145097. doi: 10.1371/journal.pone.0145097. PubMed DOI PMC

Canakis A., Kim R. Endoscopic Advances for Gastric Neoplasia Detection. Gastrointest. Endosc. Clin. N. Am. 2021;31:543–561. doi: 10.1016/j.giec.2021.03.007. PubMed DOI

Kaise M., Ohkura Y., Iizuka T., Kimura R., Nomura K., Kuribayashi Y., Yamada A., Yamashita S., Furuhata T., Kikuchi D., et al. Endocytoscopy is a promising modality with high diagnostic accuracy for gastric cancer. Endoscopy. 2015;47:19–25. doi: 10.1055/s-0034-1377965. PubMed DOI

Abad M.R.A., Inoue H., Ikeda H., Manolakis A., Rodriguez de Santiago E., Sharma A., Fujiyoshi Y., Fukuda H., Sumi K., Onimaru M., et al. Utilizing fourth-generation endocytoscopy and the ‘enlarged nuclear sign’ for in vivo diagnosis of early gastric cancer. Endosc. Int. Open. 2019;7:E1002–E1007. doi: 10.1055/a-0957-2866. PubMed DOI PMC

Park J.C., Park Y., Kim H.K., Jo J.H., Park C.H., Kim E.H., Jung D.H., Chung H., Shin S.K., Lee S.K., et al. Probe-based confocal laser endomicroscopy in the margin delineation of early gastric cancer for endoscopic submucosal dissection. J. Gastroenterol. Hepatol. 2017;32:1046–1054. doi: 10.1111/jgh.13635. PubMed DOI

Kobayashi M., Tajiri H., Seike E., Shitaya M., Tounou S., Mine M., Oba K. Detection of early gastric cancer by a real-time autofluorescence imaging system. Cancer Lett. 2001;165:155–159. doi: 10.1016/S0304-3835(01)00405-0. PubMed DOI

Tada K., Oda I., Yokoi C., Taniguchi T., Sakamoto T., Suzuki H., Nonaka S., Yoshinaga S., Saito Y., Gotoda T. Pilot study on clinical effectiveness of autofluorescence imaging for early gastric cancer diagnosis by less experienced endoscopists. Diagn. Ther. Endosc. 2011;2011:419136. doi: 10.1155/2011/419136. PubMed DOI PMC

Testoni P.A., Mangiavillano B. Optical coherence tomography in detection of dysplasia and cancer of the gastrointestinal tract and bilio-pancreatic ductal system. World J. Gastroenterol. 2008;14:6444–6452. doi: 10.3748/wjg.14.6444. PubMed DOI PMC

Kanzaki H., Takenaka R., Kawahara Y., Kawai D., Obayashi Y., Baba Y., Sakae H., Gotoda T., Kono Y., Miura K., et al. Linked color imaging (LCI), a novel image-enhanced endoscopy technology, emphasizes the color of early gastric cancer. Endosc. Int. Open. 2017;5:E1005–E1013. doi: 10.1055/s-0043-117881. PubMed DOI PMC

Shinozaki S., Osawa H., Hayashi Y., Lefor A.K., Yamamoto H. Linked color imaging for the detection of early gastrointestinal neoplasms. Therap. Adv. Gastroenterol. 2019;12:1756284819885246. doi: 10.1177/1756284819885246. PubMed DOI PMC

Hoffman A., Manner H., Rey J.W., Kiesslich R. A guide to multimodal endoscopy imaging for gastrointestinal malignancy—an early indicator. Nat. Rev. Gastroenterol. Hepatol. 2017;14:421–434. doi: 10.1038/nrgastro.2017.46. PubMed DOI

Ali H., Yasmin M., Sharif M., Rehmani M.H. Computer assisted gastric abnormalities detection using hybrid texture descriptors for chromoendoscopy images. Comput. Methods Programs Biomed. 2018;157:39–47. doi: 10.1016/j.cmpb.2018.01.013. PubMed DOI

Tang D., Wang L., Ling T., Lv Y., Ni M., Zhan Q., Fu Y., Zhuang D., Guo H., Dou X., et al. Development and validation of a real-time artificial intelligence-assisted system for detecting early gastric cancer: A multicentre retrospective diagnostic study. EBioMedicine. 2020;62:103146. doi: 10.1016/j.ebiom.2020.103146. PubMed DOI PMC

Jiang K., Jiang X., Pan J., Wen Y., Huang Y., Weng S., Lan S., Nie K., Zheng Z., Ji S., et al. Current Evidence and Future Perspective of Accuracy of Artificial Intelligence Application for Early Gastric Cancer Diagnosis With Endoscopy: A Systematic and Meta-Analysis. Front. Med. 2021;8:629080. doi: 10.3389/fmed.2021.629080. PubMed DOI PMC

Hsiao Y.J., Wen Y.C., Lai W.Y., Lin Y.Y., Yang Y.P., Chien Y., Yarmishyn A.A., Hwang D.K., Lin T.C., Chang Y.C., et al. Application of artificial intelligence-driven endoscopic screening and diagnosis of gastric cancer. World J. Gastroenterol. 2021;27:2979–2993. doi: 10.3748/wjg.v27.i22.2979. PubMed DOI PMC

Ueyama H., Kato Y., Akazawa Y., Yatagai N., Komori H., Takeda T., Matsumoto K., Ueda K., Matsumoto K., Hojo M., et al. Application of artificial intelligence using a convolutional neural network for diagnosis of early gastric cancer based on magnifying endoscopy with narrow-band imaging. J. Gastroenterol. Hepatol. 2021;36:482–489. doi: 10.1111/jgh.15190. PubMed DOI PMC

Wu L., He X., Liu M., Xie H., An P., Zhang J., Zhang H., Ai Y., Tong Q., Guo M., et al. Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: A randomized controlled trial. Endoscopy. 2021;53:1199–1207. doi: 10.1055/a-1350-5583. PubMed DOI

Han J.S., Jang J.S., Ryu H.C., Kim M.C., Kim K.H., Kim D.K. Risk factors associated with multiple and missed gastric neoplastic lesions after endoscopic resection: Prospective study at a single institution in south Korea. Hepatogastroenterology. 2015;62:512–517. PubMed

Oka K., Iwai N., Okuda T., Hara T., Inada Y., Tsuji T., Komaki T., Sakagami J., Naito Y., Kagawa K., et al. Clinical Features of False-Negative Early Gastric Cancers: A Retrospective Study of Endoscopic Submucosal Dissection Cases. Gastroenterol. Res. Pract. 2021;2021:6635704. doi: 10.1155/2021/6635704. PubMed DOI PMC

Pimenta-Melo A.R., Monteiro-Soares M., Libânio D., Dinis-Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal endoscopy: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2016;28:1041–1049. doi: 10.1097/MEG.0000000000000657. PubMed DOI

Gotoda T., Yanagisawa A., Sasako M., Ono H., Nakanishi Y., Shimoda T., Kato Y. Incidence of lymph node metastasis from early gastric cancer: Estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–225. doi: 10.1007/PL00011720. PubMed DOI

Hirasawa T., Gotoda T., Miyata S., Kato Y., Shimoda T., Taniguchi H., Fujisaki J., Sano T., Yamaguchi T. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer. 2009;12:148–152. doi: 10.1007/s10120-009-0515-x. PubMed DOI

Oda I., Gotoda T., Hamanaka H., Eguchi T., Saito Y., Matsuda T., Bhandari P., Emura F., Saito D., Ono H. Endoscopic submucosal dissection for early gastric cancer: Technical feasibility, operation time and complications from a large consecutive series. Dig. Endosc. Off. J. Jpn. Gastroenterol. Endosc. Soc. 2005;17:54–58. doi: 10.1111/j.1443-1661.2005.00459.x. DOI

Hasuike N., Ono H., Boku N., Mizusawa J., Takizawa K., Fukuda H., Oda I., Doyama H., Kaneko K., Hori S., et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): The Japan Clinical Oncology Group study (JCOG0607) Gastric Cancer. 2018;21:114–123. doi: 10.1007/s10120-017-0704-y. PubMed DOI

Probst A., Schneider A., Schaller T., Anthuber M., Ebigbo A., Messmann H. Endoscopic submucosal dissection for early gastric cancer: Are expanded resection criteria safe for Western patients? Endoscopy. 2017;49:855–865. doi: 10.1055/s-0043-110672. PubMed DOI

Facciorusso A., Antonino M., Di Maso M., Muscatiello N. Endoscopic submucosal dissection vs. endoscopic mucosal resection for early gastric cancer: A meta-analysis. World J. Gastrointest. Endosc. 2014;6:555–563. doi: 10.4253/wjge.v6.i11.555. PubMed DOI PMC

Lian J., Chen S., Zhang Y., Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest. Endosc. 2012;76:763–770. doi: 10.1016/j.gie.2012.06.014. PubMed DOI

Park Y.M., Cho E., Kang H.Y., Kim J.M. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: A systematic review and metaanalysis. Surg. Endosc. 2011;25:2666–2677. doi: 10.1007/s00464-011-1627-z. PubMed DOI

Pimentel-Nunes P., Dinis-Ribeiro M., Ponchon T., Repici A., Vieth M., De Ceglie A., Amato A., Berr F., Bhandari P., Bialek A., et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47:829–854. doi: 10.1055/s-0034-1392882. PubMed DOI

Ono H., Yao K., Fujishiro M., Oda I., Nimura S., Yahagi N., Iishi H., Oka M., Ajioka Y., Ichinose M., et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig. Endosc. 2016;28:3–15. doi: 10.1111/den.12518. PubMed DOI

The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest. Endosc. 2003;58((Suppl. 6)):S3–S43. doi: 10.1016/S0016-5107(03)02159-X. PubMed DOI

Abe S., Oda I., Shimazu T., Kinjo T., Tada K., Sakamoto T., Kusano C., Gotoda T. Depth-predicting score for differentiated early gastric cancer. Gastric Cancer. 2011;14:35–40. doi: 10.1007/s10120-011-0002-z. PubMed DOI

ASGE Technology Committee. Aslanian H.R., Sethi A., Bhutani M.S., Goodman A.J., Krishnan K., Lichtenstein D.R., Melson J., Navaneethan U., Pannala R., et al. ASGE guideline for endoscopic full-thickness resection and submucosal tunnel endoscopic resection. VideoGIE. 2019;4:343–350. doi: 10.1016/j.vgie.2019.03.010. PubMed DOI PMC

van der Post R.S., Vogelaar I.P., Carneiro F., Guilford P., Huntsman D., Hoogerbrugge N., Caldas C., Schreiber K.E., Hardwick R.H., Ausems M.G., et al. Hereditary diffuse gastric cancer: Updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J. Med. Genet. 2015;52:361–374. doi: 10.1136/jmedgenet-2015-103094. PubMed DOI PMC

Monahan K.J., Bradshaw N., Dolwani S., Desouza B., Dunlop M.G., East J.E., Ilyas M., Kaur A., Lalloo F., Latchford A., et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG) Gut. 2020;69:411–444. doi: 10.1136/gutjnl-2019-319915. PubMed DOI PMC

van Leerdam M.E., Roos V.H., van Hooft J.E., Balaguer F., Dekker E., Kaminski M.F., Latchford A., Neumann H., Ricciardiello L., Rupińska M., et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2019;51:1082–1093. doi: 10.1055/a-1016-4977. PubMed DOI

Daly M.B., Pal T., Berry M.P., Buys S.S., Dickson P., Domchek S.M., Elkhanany A., Friedman S., Goggins M., Hutton M.L., et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021;19:77–102. doi: 10.6004/jnccn.2021.0001. PubMed DOI